Novo Nordisk A/S has unveiled promising results from its phase 3 REAL8 basket study, showcasing the efficacy and safety of once-weekly Sogroya (somapacitan) in children with various growth disorders. The study, part of the broader REAL clinical trial, compared the long-acting growth hormone to the once-daily Norditropin (somatropin), revealing comparable clinical outcomes and safety profiles after 52 weeks of treatment. This marks a significant step forward in reducing the treatment burden for children and their families.

The REAL8 trial focused on children born small for gestational age (SGA), those with Noonan syndrome (NS), and individuals with idiopathic short stature (ISS). Notably, Sogroya not only matched the efficacy of daily growth hormone treatments but also demonstrated superiority in certain subgroups, including children with NS and those born SGA receiving lower doses of daily growth hormone. These findings highlight the potential of Sogroya to offer a more convenient and equally effective treatment option for pediatric growth disorders.

Adherence to treatment is a critical challenge in managing growth disorders, with the burden of daily injections often leading to decreased compliance. The introduction of a once-weekly treatment like Sogroya could significantly alleviate this issue, improving treatment outcomes and quality of life for affected children. Novo Nordisk's commitment to innovation in this space is evident, as the company seeks to address unmet needs in pediatric endocrinology.

With regulatory submissions for Sogroya in the European Union and the U.S. based on the REAL8 and REAL9 studies, the future looks promising for this novel treatment. As the medical community awaits further developments, the data presented at the joint Congress of ESPE and ESE underscore the potential of Sogroya to transform the treatment landscape for children with growth disorders, offering hope for easier management and better adherence to therapy.

TGS, the Oslo-based energy data provider, has been awarded a significant ocean bottom node (OBN) acquisition contract in the Gulf of Mexico, marking another strategic win in one of the company's core markets. The 4D monitor survey is scheduled to commence in the fourth quarter of 2025 and will span approximately four and a half months. This contract represents continued confidence in TGS's capabilities from the international oil company client, though the specific customer identity remains undisclosed.

The contract was notably absent from TGS's booked position disclosed in the company's second quarter 2025 presentation, indicating a recent acquisition for the seismic data specialist. The Gulf of Mexico remains a critical region for offshore energy production, and 4D seismic monitoring plays an essential role in optimizing reservoir management and production efficiency for major operators in the region.

Kristian Johansen, CEO of TGS, emphasized the significance of securing business from repeat customers, stating that the client values TGS's OBN technology and proven track record of project execution. "The client is confident we will deliver high-quality data and insights to optimize production from one of their highest producing facilities in the Gulf of Mexico," Johansen commented, highlighting the operational importance of the project for the customer's production optimization efforts.

TGS's expertise in OBN technology positions the company as a trusted partner for international oil companies seeking to maximize recovery from existing assets. The 4D seismic approach allows operators to monitor reservoir changes over time, providing critical data for production optimization decisions. This latest contract win reinforces TGS's strong position in the Gulf of Mexico market and demonstrates the ongoing demand for advanced seismic monitoring solutions in mature offshore basins.